Rolling with the punches: Generics firms innovate, expand scope to stay competitiveAs they continue to navigate pandemic headwinds, generics firms look to broaden their portfolios and vertically integrate to keep competitive. Roundup: Recent generic launchesTaking a look at some of the innovative new generics making their debut: FDA tentatively OKs Zydus Cadila’s generic Imbruvica Zydus Cadila's generic Imbruvica tablets provide a treatment for certain types of cancer. Beximco receives FDA nod for Baclofen Baclofen had a market value of more than $110 million in 2020, according to IQVIA. Nexus debuts potassium chloride in water for injection Potassium chloride injection is indicated in the treatment of potassium deficiency states when oral replacement is not feasible. Intas, Meiji and Dong-A ST to commercialize Stelara biosimilar Biosimilar ustekinumab will provide a treatment of autoimmune and inflammatory diseases such as plaque psoriasis, Crohn's disease and ulcerative colitis. Aurobindo’s generic Adalat CC gets FDA OK The market size of the product was $95 million for the 12-month period ended May 2021, according to IQVIA data. Slayback names Pete Meyers CFO Meyers most recently served as CFO of Eagle Pharmaceuticals. Camber debuts generic Revatio OS Camber’s sildenafil for oral suspension is indicated to treat pulmonary arterial hypertension or high blood pressure in the lungs. Lupin intros Kerydin generic Branded and generic versions of the product had U.S. sales of $53 million for the year ended May 2021, according to IQVIA data. First Previous 120 121 122 123 124 Next Last
